Alan Schneyer

Title: Alan Schneyer: Innovator in Antibody and Iron Metabolism Research

Introduction

Alan Schneyer is a prominent inventor based in Concord, MA (US), known for his significant contributions to the fields of antibody development and iron metabolism regulation. With a total of 6 patents to his name, Schneyer's work has the potential to impact various medical treatments and therapies.

Latest Patents

Among his latest patents, Schneyer has developed innovative solutions such as anti-follistatin-like 3 antibodies aimed at treating diabetes. This invention provides antibodies and antigen-binding fragments that specifically bind to the human Follistatin-Like-3 (FSTL3) protein. The patent also includes compositions comprising these antibodies and methods for their application. Another notable patent focuses on methods and compositions to regulate hepcidin expression, which is crucial for iron metabolism in mammals. This invention outlines new systems and strategies to modulate the expression or activity of hepcidin, addressing diseases associated with both iron overload and deficiency.

Career Highlights

Throughout his career, Alan Schneyer has worked with reputable organizations, including The General Hospital Corporation and Fairbanks Pharmaceuticals, Inc. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.

Collaborations

Schneyer has collaborated with esteemed colleagues such as Clifford J Woolf and Tarek A Samad, further enhancing the impact of his research through shared expertise and knowledge.

Conclusion

Alan Schneyer stands out as an influential inventor whose work in antibody development and iron metabolism regulation continues to pave the way for advancements in medical treatments. His contributions are vital in addressing critical health issues related to diabetes and iron disorders.